document discussed post called zyprexa primary care presentation appears transcript speech mike bandick zyprexa brand manager gave eli lilly national sales meeting march important note zyprexa fda approved use schizophrenia bipolar disorder document appears indicate bandick encouraging salespeople market zyprexa treating two conditions bandick said intend quite simply redefine way pcps treat mood thought behavioral disturbances continue focus symptoms behaviors pcps see every day later said referencing zyprexa broad symptom efficacy mood thought behavioral disturbances seems curious lilly states market zyprexa label purposes yet term mood thought behavioral disturbances seems fair amount broader schizophrenia bipolar disorder addition schizophrenia bipolar disorder especially bipolar i much severe form bipolar comparison bipolar ii uncommon disorders highly unlikely primary care physicians would see patients conditions every day however certainly possible pcp may run across individuals manifesting much less severe disturbances may well group patients exhibited mild mood thought behavioral symptoms zyprexa marketed bandick went discuss case martha discussed case seemed much strongly resemble dementia schizophrenia bipolar disorder martha hypothetical case reps said used order sell benefits zyprexa physicians bandick said let me take quick time make one quick comment martha first thing notice martha old two things first reinforces zyprexa nursing home drug mission build primary care franchise let long term care team drive nursing home business second limits perception behavioral disturbances agitation tension anger hostility show primary care variety packages describe martha make symptoms prominent age certainly possible push get pcp recognize agitation tension anger hostility patients variety packages could well mean label vast majority people struggle particular issues neither schizophrenia bipolar disorder point i seen enough long term care team offer intelligent idea strategy though i would assume martha may involved pages later bandick stated emphasize patient benefits know difference competitor companion drugs like aricept zoloft belong calling companion classes drugs augment rather replace aricept donepezil fda approved treatment alzheimer disease zoloft approved treatment depression anxiety disorders aricept rarely used treatment schizophrenia zoloft sensible treatment symptoms either schizophrenia bipolar disorder idea prescribe zyprexa along aricept seems related case martha stated earlier hypothetical patient discussed sales materials whose symptoms appear resemble dementia aricept frequently used opposed schizophrenia bipolar bandick speech lends credibility idea zyprexa sold add dementia treatment also note later document bandick states expect approval summer intramuscular formulation add two crucial words label agitation dementia seems lilly expected zyprexa would approved dementia thus possible getting word early zyprexa dementia would allowable per fda marketing regulations although approval never occurred doctor doctor marketing outside sales reps drug companies frequently use practicing academic physicians help market products known peer peer marketing current document bandick quoted saying regarding peer peer completed second two speaker training programs unleashed psychs pcp chomping bit help sell zyprexa bandick also stated must utilize trained speaker educate pcps geodon competitor medication drawbacks especially zyprexa advantages benefits patients likely nothing illegal practice practicing academic physicians salespeople certainly raise conflicts interest physicians may apt believe physicians opposed sales rep line sales rep peer physician blurs significantly physicians paid trained sponsoring company lilly document quotes cited zy pdf i thank furious seasons hosting well zyprexa documents additional thanks alex berenson new york times first discussed martha earlier article